“This medical device will soon be available to users of the National Health Service (SNS),” stated Infarmed in a communiqué.
The Accu-Chek SmartGuide is a real-time continuous glucose monitoring sensor that will soon be available for patients with type 1 diabetes who are 18 years or older and use multiple daily doses of insulin or non-integrated infusion systems.
With 14 days of use per sensor, the Accu-Chek SmartGuide will become an alternative to the Freestyle Libre 2 Plus, which until now was the only subsidized device, according to Infarmed.
“Interstitial glucose monitoring technology allows for a continuous, accurate, and comfortable assessment, avoiding frequent pricks and contributing to better metabolic control,” it emphasized.
Infarmed adds that the measure reinforces the SNS’s commitment to “promoting the quality of life of people with diabetes, ensuring equitable access to advanced health solutions for those who need them.”
